MA50418A - Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse - Google Patents
Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèseInfo
- Publication number
- MA50418A MA50418A MA050418A MA50418A MA50418A MA 50418 A MA50418 A MA 50418A MA 050418 A MA050418 A MA 050418A MA 50418 A MA50418 A MA 50418A MA 50418 A MA50418 A MA 50418A
- Authority
- MA
- Morocco
- Prior art keywords
- synthesis
- salts
- methods
- substituted heterocyclic
- heterocyclic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762573917P | 2017-10-18 | 2017-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50418A true MA50418A (fr) | 2021-04-07 |
Family
ID=66173899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050418A MA50418A (fr) | 2017-10-18 | 2018-10-18 | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse |
Country Status (16)
Country | Link |
---|---|
US (2) | US20200247790A1 (fr) |
EP (1) | EP3697762A4 (fr) |
JP (2) | JP2021500334A (fr) |
KR (1) | KR20200101330A (fr) |
CN (1) | CN111417628A (fr) |
AU (2) | AU2018353122B2 (fr) |
BR (1) | BR112020007632A2 (fr) |
CA (1) | CA3079273A1 (fr) |
CL (1) | CL2020001009A1 (fr) |
CO (1) | CO2020005944A2 (fr) |
EA (1) | EA202090959A1 (fr) |
IL (2) | IL301746B2 (fr) |
MA (1) | MA50418A (fr) |
MX (2) | MX2020007152A (fr) |
SG (1) | SG11202003225YA (fr) |
WO (1) | WO2019079540A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110446495B (zh) | 2017-02-17 | 2023-09-05 | 特维娜有限公司 | 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法 |
CN118021814A (zh) | 2017-04-21 | 2024-05-14 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
RS62818B1 (sr) | 2017-10-18 | 2022-02-28 | Incyte Corp | Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma |
SI3847175T1 (sl) | 2018-09-05 | 2024-05-31 | Incyte Corporation | Kristalinične oblike zaviralca fosfoinozitid 3-kinaze (pi3k) |
CN114249785B (zh) * | 2020-09-23 | 2024-04-05 | 常州方圆制药有限公司 | 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法 |
CN116406268A (zh) * | 2020-10-27 | 2023-07-07 | 特维娜有限公司 | δ-阿片样物质调节剂的结晶和无定形形式 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004272288B2 (en) * | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
MX362412B (es) * | 2005-11-01 | 2019-01-15 | Targegen Inc | Inhibidores de biaril meta-pirimidina de cinasas. |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
EP3154957B1 (fr) * | 2014-06-16 | 2019-11-20 | Fundacion para la Investigacion Medica Aplicada | Nouveaux composés utilisés comme inhibiteurs doubles d'histone méthyltransférases et d'adn méthyltransférases |
EP3157524A4 (fr) * | 2014-06-23 | 2017-12-06 | Genentech, Inc. | Méthodes de traitement du cancer et de prévention de la résistance aux médicaments anticancéreux |
KR20230130747A (ko) * | 2016-04-15 | 2023-09-12 | 에피자임, 인코포레이티드 | Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물 |
AU2017382830A1 (en) * | 2016-12-19 | 2019-06-13 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof |
AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
JP2021500327A (ja) * | 2017-10-18 | 2021-01-07 | エピザイム,インコーポレイティド | 免疫療法にehmt2阻害剤を使用する方法 |
-
2018
- 2018-10-18 WO PCT/US2018/056428 patent/WO2019079540A1/fr active Application Filing
- 2018-10-18 MA MA050418A patent/MA50418A/fr unknown
- 2018-10-18 CN CN201880077022.4A patent/CN111417628A/zh active Pending
- 2018-10-18 SG SG11202003225YA patent/SG11202003225YA/en unknown
- 2018-10-18 IL IL301746A patent/IL301746B2/en unknown
- 2018-10-18 AU AU2018353122A patent/AU2018353122B2/en active Active
- 2018-10-18 MX MX2020007152A patent/MX2020007152A/es unknown
- 2018-10-18 EA EA202090959A patent/EA202090959A1/ru unknown
- 2018-10-18 JP JP2020521599A patent/JP2021500334A/ja not_active Withdrawn
- 2018-10-18 US US16/756,565 patent/US20200247790A1/en not_active Abandoned
- 2018-10-18 EP EP18869308.9A patent/EP3697762A4/fr not_active Withdrawn
- 2018-10-18 BR BR112020007632-5A patent/BR112020007632A2/pt unknown
- 2018-10-18 KR KR1020207013781A patent/KR20200101330A/ko not_active Ceased
- 2018-10-18 CA CA3079273A patent/CA3079273A1/fr active Pending
-
2020
- 2020-04-15 CL CL2020001009A patent/CL2020001009A1/es unknown
- 2020-04-16 IL IL273974A patent/IL273974B2/en unknown
- 2020-05-15 CO CONC2020/0005944A patent/CO2020005944A2/es unknown
- 2020-07-13 MX MX2024012124A patent/MX2024012124A/es unknown
-
2022
- 2022-03-24 US US17/703,155 patent/US20220324851A1/en active Pending
-
2023
- 2023-01-11 JP JP2023002371A patent/JP2023036991A/ja active Pending
-
2024
- 2024-02-22 AU AU2024201165A patent/AU2024201165A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3079273A1 (fr) | 2019-04-25 |
EA202090959A1 (ru) | 2020-07-13 |
SG11202003225YA (en) | 2020-05-28 |
BR112020007632A2 (pt) | 2020-09-29 |
EP3697762A4 (fr) | 2021-04-07 |
AU2018353122B2 (en) | 2023-11-23 |
IL301746B2 (en) | 2025-01-01 |
CN111417628A (zh) | 2020-07-14 |
US20220324851A1 (en) | 2022-10-13 |
MX2024012124A (es) | 2025-02-10 |
JP2023036991A (ja) | 2023-03-14 |
IL273974A (en) | 2020-05-31 |
MX2020007152A (es) | 2020-12-10 |
CO2020005944A2 (es) | 2020-07-31 |
IL301746B1 (en) | 2024-09-01 |
WO2019079540A1 (fr) | 2019-04-25 |
KR20200101330A (ko) | 2020-08-27 |
CL2020001009A1 (es) | 2020-12-18 |
IL273974B1 (en) | 2023-04-01 |
EP3697762A1 (fr) | 2020-08-26 |
US20200247790A1 (en) | 2020-08-06 |
AU2024201165A1 (en) | 2024-03-14 |
JP2021500334A (ja) | 2021-01-07 |
IL301746A (en) | 2023-05-01 |
AU2018353122A1 (en) | 2020-06-04 |
IL273974B2 (en) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47233A (fr) | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation | |
MA50418A (fr) | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse | |
EP3402799A4 (fr) | Composés hétérocycliques utilisés comme inhibiteurs du vrs | |
CY1124187T1 (el) | Ετεροκυκλικα αμιδια ως αναστολεις κινασης | |
MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
FR24C1009I2 (fr) | Composés utilisés comme inhibiteurs de kinase | |
MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
EP3389783A4 (fr) | Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase | |
MA46045A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA45669A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA44860A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA55633A (fr) | Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock | |
MX378499B (es) | Compuestos antifungicos. | |
MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
EP3331880A4 (fr) | Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques | |
MA46531A (fr) | Dérivés d'azétidine ou de cyclobutane 1,3-disubstitués utilisés comme inhibiteurs de la prostaglandine d synthase hématopoïétique (h-pgds) | |
JOP20190174B1 (ar) | مثبطات jak1 انتقائية | |
MA40302A1 (fr) | Dérivés de carbazole | |
MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
MA51864A (fr) | Méthodes d'identification de composés | |
EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
MA50609A (fr) | Énantiomères de thiazoles substitués utilisés comme composés antiviraux | |
EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения |